{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:18:26Z","timestamp":1778152706440,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20260817"],"award-info":[{"award-number":["20260817"]}]},{"name":"Medical Science Research Project of Hebei","award":["20260817"],"award-info":[{"award-number":["20260817"]}]},{"name":"Medical Science Research Project of Hebei","award":["20260817"],"award-info":[{"award-number":["20260817"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44422-7","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T03:35:04Z","timestamp":1774236904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated platform for linezolid combinations against rifampicin-resistant Mycobacterium tuberculosis: synergy, macrophage apoptosis, and immune modulation"],"prefix":"10.1038","volume":"16","author":[{"given":"Dan","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"44422_CR1","unstructured":"World Health Organization. Drug-resistant TB. In: 1.3 Drug-resistant TB - Global Tuberculosis Report 2024. Geneva: WHO. at (2024). https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024\/tb-disease-burden\/1-3-drug-resistant-tb"},{"key":"44422_CR2","doi-asserted-by":"publisher","first-page":"126674","DOI":"10.1016\/j.micres.2020.126674","volume":"246","author":"RD Kanabalan","year":"2021","unstructured":"Kanabalan, R. D. et al. Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery. Microbiol. Res. 246, 126674 (2021).","journal-title":"Microbiol. Res."},{"key":"44422_CR3","doi-asserted-by":"publisher","first-page":"001458","DOI":"10.1099\/mic.0.001458","volume":"170","author":"SJ Dechow","year":"2024","unstructured":"Dechow, S. J. & Abramovitch, R. B. Targeting Mycobacterium tuberculosis pH-driven adaptation. Microbiology (Reading). 170, 001458 (2024).","journal-title":"Microbiology (Reading)"},{"key":"44422_CR4","doi-asserted-by":"publisher","first-page":"e25122","DOI":"10.1002\/jcla.25122","volume":"38","author":"N Mohammadnabi","year":"2024","unstructured":"Mohammadnabi, N. et al. Mycobacterium tuberculosis: The mechanism of pathogenicity, immune responses, and diagnostic challenges. J. Clin. Lab. Anal. 38, e25122 (2024).","journal-title":"J. Clin. Lab. Anal."},{"key":"44422_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie, F. et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl. J. Med. 387, 810\u2013823 (2022).","journal-title":"N Engl. J. Med."},{"key":"44422_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00228-023-03500-9","volume":"79","author":"F Elbarbry","year":"2023","unstructured":"Elbarbry, F. & Moshirian, N. Linezolid-associated serotonin toxicity: A systematic review. Eur. J. Clin. Pharmacol. 79, 875\u2013883 (2023).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"44422_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/pathogens11040381","volume":"11","author":"P Howell","year":"2022","unstructured":"Howell, P. et al. Treatment of rifampicin-resistant tuberculosis disease and infection in children: Key Updates, challenges and opportunities. Pathogens 11, 381 (2022).","journal-title":"Pathogens"},{"key":"44422_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"BT Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa, B. T. et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 12, 117\u2013128 (2024).","journal-title":"Lancet Respir Med."},{"key":"44422_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12879-016-2151-5","volume":"17","author":"P Ding","year":"2017","unstructured":"Ding, P., Li, X., Jia, Z. & Lu, Z. Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: A systematic review and spatio-temporal analysis. BMC Infect. Dis. 17, 57 (2017).","journal-title":"BMC Infect. Dis."},{"key":"44422_CR10","first-page":"104009","volume":"79","author":"MA Khan","year":"2022","unstructured":"Khan, M. A. et al. MDR-TB in Pakistan: Challenges, efforts, and recommendations. Ann. Med. Surg. (Lond). 79, 104009 (2022).","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"44422_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.tim.2020.04.010","volume":"28","author":"NC Howard","year":"2020","unstructured":"Howard, N. C. & Khader, S. A. Immunometabolism during Mycobacterium tuberculosis infection. Trends Microbiol. 28, 832\u2013850 (2020).","journal-title":"Trends Microbiol."},{"key":"44422_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000449037","volume":"92","author":"HJF Salzer","year":"2016","unstructured":"Salzer, H. J. F. et al. Personalized medicine for chronic respiratory infectious diseases: Tuberculosis, nontuberculous mycobacterial pulmonary diseases, and chronic pulmonary aspergillosis. Respiration 92, 199\u2013214 (2016).","journal-title":"Respiration"},{"key":"44422_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.37757\/MR2017.V19.N1.3","volume":"19","author":"D Lemus","year":"2017","unstructured":"Lemus, D. et al. Antituberculosis drug resistance in pulmonary isolates of Mycobacterium tuberculosis, Cuba 2012\u20132014. MEDICC Rev. 19, 10\u201315 (2017).","journal-title":"MEDICC Rev."},{"key":"44422_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/antibiotics9090569","volume":"9","author":"MF Sim\u00f5es","year":"2020","unstructured":"Sim\u00f5es, M. F., Ottoni, C. A. & Antunes, A. Mycogenic metal nanoparticles for the treatment of mycobacterioses. Antibiotics. 9, 569 (2020).","journal-title":"Antibiotics"},{"key":"44422_CR15","doi-asserted-by":"publisher","first-page":"105507","DOI":"10.1016\/j.micpath.2022.105507","volume":"165","author":"CX Liu","year":"2022","unstructured":"Liu, C. X., Zhao, X., Wang, L. & Yang, Z. C. Quinoline derivatives as potential anti-tubercular agents: Synthesis, molecular docking and mechanism of action. Microb. Pathog. 165, 105507 (2022).","journal-title":"Microb. Pathog"},{"key":"44422_CR16","doi-asserted-by":"publisher","first-page":"e0160109","DOI":"10.1371\/journal.pone.0160109","volume":"11","author":"VCD Micheletti","year":"2016","unstructured":"Micheletti, V. C. D., Kritski, A. L. & Braga, J. U. Clinical features and treatment outcomes of patients with drug-resistant and drug-sensitive tuberculosis: A historical cohort study in Porto Alegre, Brazil. PLoS One. 11, e0160109 (2016).","journal-title":"PLoS One"},{"key":"44422_CR17","doi-asserted-by":"publisher","first-page":"e0274426","DOI":"10.1371\/journal.pone.0274426","volume":"17","author":"M Getahun","year":"2022","unstructured":"Getahun, M., Blumberg, H. M., Ameni, G., Beyene, D. & Kempker, R. R. Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS One. 17, e0274426 (2022).","journal-title":"PLoS One"},{"key":"44422_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","volume":"17","author":"A Sharma","year":"2017","unstructured":"Sharma, A. et al. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: A mathematical modelling study. Lancet Infect. Dis. 17, 707\u2013715 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"44422_CR19","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3201\/eid2509.190105","volume":"25","author":"PK Singh","year":"2019","unstructured":"Singh, P. K. & Jain, A. Limited scope of shorter drug regimen for MDR TB caused by high resistance to fluoroquinolone. Emerg. Infect. Dis. 25, 1760\u20131762 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"44422_CR20","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s10096-021-04187-5","volume":"40","author":"J Gao","year":"2021","unstructured":"Gao, J. et al. Stepwise selection of mutation conferring fluroquinolone resistance: Multisite MDR-TB cohort study. Eur. J. Clin. Microbiol. Infect. Dis. 40, 1767\u20131771 (2021).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"44422_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","volume":"14","author":"S Wasserman","year":"2016","unstructured":"Wasserman, S., Meintjes, G. & Maartens, G. Linezolid in the treatment of drug-resistant tuberculosis: The challenge of its narrow therapeutic index. Expert Rev. Anti Infect. Ther. 14, 901\u2013915 (2016).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"44422_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1473-3099(18)30480-8","volume":"19","author":"JK Lee","year":"2019","unstructured":"Lee, J. K. et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: A prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect. Dis. 19, 46\u201355 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"44422_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1541-7786.MCR-18-0354","volume":"17","author":"R Bagheri-Yarmand","year":"2019","unstructured":"Bagheri-Yarmand, R. et al. Combinations of tyrosine kinase inhibitor and ERAD inhibitor promote oxidative stress\u2013induced apoptosis through ATF4 and KLF9 in medullary thyroid cancer. Mol. Cancer Res. 17, 751\u2013760 (2019).","journal-title":"Mol. Cancer Res."},{"key":"44422_CR24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3389\/fimmu.2020.01609","volume":"11","author":"DJ Cox","year":"2020","unstructured":"Cox, D. J. et al. Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1\u03b2, and T helper cell responses to Mycobacterium tuberculosis. Front. Immunol. 11, 1609 (2020).","journal-title":"Front. Immunol."},{"key":"44422_CR25","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.csbj.2021.04.034","volume":"19","author":"P Singh","year":"2021","unstructured":"Singh, P. et al. Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis. Comput. Struct. Biotechnol. J. 19, 2423\u20132446 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"44422_CR26","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1007\/s11033-022-07404-2","volume":"49","author":"P Bakhtiyariniya","year":"2022","unstructured":"Bakhtiyariniya, P., Khosravi, A. D., Hashemzadeh, M. & Savari, M. Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran. Mol. Biol. Rep. 49, 6135\u20136143 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"44422_CR27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/pharmaceutics12121196","volume":"12","author":"ZM Tan","year":"2020","unstructured":"Tan, Z. M. et al. Novel approaches for the treatment of pulmonary tuberculosis. Pharmaceutics 12, 1196 (2020).","journal-title":"Pharmaceutics"},{"key":"44422_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","volume":"38","author":"G Ramachandran","year":"2015","unstructured":"Ramachandran, G. & Swaminathan, S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 38, 253\u2013269 (2015).","journal-title":"Drug Saf."},{"key":"44422_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10096-014-2202-z","volume":"34","author":"T Jagielski","year":"2015","unstructured":"Jagielski, T. et al. A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 34, 41\u201353 (2015).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"44422_CR30","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1099\/jmm.0.000637","volume":"66","author":"SM Lee","year":"2017","unstructured":"Lee, S. M. et al. Resistance mechanisms of linezolid-nonsusceptible enterococci in Korea: Low rate of 23S rRNA mutations in Enterococcus faecium. J. Med. Microbiol. 66, 1730\u20131735 (2017).","journal-title":"J. Med. Microbiol."},{"key":"44422_CR31","doi-asserted-by":"publisher","first-page":"13812","DOI":"10.3390\/ijms241813812","volume":"24","author":"M Tang","year":"2023","unstructured":"Tang, M. et al. The properties of linezolid, rifampicin, and vancomycin, as well as the mechanism of action of pentamidine, determine their synergy against gram-negative bacteria. Int. J. Mol. Sci. 24, 13812 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"44422_CR32","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.4049\/jimmunol.1600856","volume":"197","author":"CE Dodd","year":"2016","unstructured":"Dodd, C. E., Pyle, C. J., Glowinski, R., Rajaram, M. V. S. & Schlesinger, L. S. CD36-mediated uptake of surfactant lipids by human macrophages promotes intracellular growth of Mycobacterium tuberculosis. J. Immunol. 197, 4727\u20134735(2016).","journal-title":"J. Immunol."},{"key":"44422_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jmoldx.2021.02.004","volume":"23","author":"M Beutler","year":"2021","unstructured":"Beutler, M. et al. Rapid Tuberculosis diagnostics including molecular first- and second-line resistance testing based on a novel microfluidic DNA extraction cartridge. J. Mol. Diagn. 23, 643\u2013650 (2021).","journal-title":"J. Mol. Diagn."},{"key":"44422_CR34","doi-asserted-by":"publisher","first-page":"943545","DOI":"10.3389\/fcimb.2022.943545","volume":"12","author":"D Liebenberg","year":"2022","unstructured":"Liebenberg, D., Gordhan, B. G. & Kana, B. D. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front. Cell. Infect. Microbiol. 12, 943545 (2022).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"44422_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jiph.2023.01.014","volume":"16","author":"T Zhang","year":"2023","unstructured":"Zhang, T. et al. The global, regional, and national burden of tuberculosis in 204 countries and territories, 1990\u20132019. J. Infect. Public Health. 16, 368\u2013375 (2023).","journal-title":"J. Infect. Public Health"},{"key":"44422_CR36","first-page":"2628913","volume":"2016","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. Resistance to second-line antituberculosis drugs and delay in drug susceptibility testing among multidrug-resistant tuberculosis patients in Shanghai. Biomed. Res. Int. 2016, 2628913 (2016).","journal-title":"Biomed. Res. Int."},{"key":"44422_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2\u201313 (2011).","journal-title":"Mol. Cell. Endocrinol."},{"key":"44422_CR38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12879-015-1205-4","volume":"15","author":"AH Van\u2019t Hoog","year":"2015","unstructured":"Van\u2019t Hoog, A. H. et al. The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study. BMC Infect. Dis. 15, 473 (2015).","journal-title":"BMC Infect. Dis."},{"key":"44422_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jsbmb.2017.05.014","volume":"172","author":"YN Liang","year":"2017","unstructured":"Liang, Y. N. et al. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. J. Steroid Biochem. Mol. Biol. 172, 62\u201368 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"44422_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1086\/501749","volume":"21","author":"AG Matlow","year":"2000","unstructured":"Matlow, A. G., Harrison, A., Monteath, A., Roach, P. & Balfe, J. W. Nosocomial transmission of tuberculosis (TB) associated with care of an infant with peritoneal TB. Infect. Control Hosp. Epidemiol. 21, 222\u2013223 (2000).","journal-title":"Infect. Control Hosp. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44422-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44422-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44422-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:03:15Z","timestamp":1778151795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44422-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44422"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44422-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not involve human participants or animals. The standard strain of\n                      Mycobacterium tuberculosis\n                      H37Rv (ATCC 27295) was obtained from the Key Laboratory of Pulmonary Diseases, Hebei Chest Hospital, and therefore did not require ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"14591"}}